Hi
Last week, MindBio enrolled the final patient in its landmark Phase 2B trial,
trial testing MB22001 in patients with Major Depressive Disorder.
Even I have been surprised by the data from our trials as we slowly progress the drug to the next phase of clinical development. If Phase 2B results are positive, this will be a significant next step towards commercialisation and the most significant affirmation that microdosing is an effective treatment modality using psychedelic medicines.
This is the most advanced take-home use case of a psychedelic medicine entering late stage clinical trials.
Already, from previous trials, we have seen dramatic improvements in mood, sleep, anxiety, quality of life and anti-depressant effects sustained 6 months post an 8 week treatment cycle with MB22001. This medicine addresses the myriad of symptoms reported by depressed patients who commonly will experience disrupted sleep, lack of energy, social withdrawal and low mood.
A microdose of MB22001 is sub-hallucinogenic and can be taken by patients safely at home, and then they can get on with their day in the same way they would if they were taking any other medication. MindBio remains the only company in the world to have approvals for the take home use of this type of medicine in clinical trials.
We invite you to join us in support of creating a brighter future for mental health.
Stay Well!
JUSTIN HANKA
Chief Executive Officer & Co-Founder
MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)
0 comments